Diabetes Drugs To Feature Black Box Warning

Law360, New York (August 15, 2007, 12:00 AM EDT) -- Just days after deciding not to pull GlaxoSmithKline PLC's Avandia Type 2 diabetes drug from the shelves, the U.S. Food and Drug Administration has instead gotten the company and other manufacturers of antidiabetic medications to update their labels to reflect the risks of heart failure.

GSK and Takeda Pharmaceutical Co., the makers of Avandia, Actos, Avandaryl, Avandamet and Duetact—all drugs that help control blood sugar in adults with type 2 diabetes—agreed on Tuesday to update their boxes with the FDA's strongest form of a warning....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.